Jaguar Health, Inc.

BUS INESS BUSINESS Jaguar Health, Inc. ( Jaguar ), in conjunction with Jaguar family company Napo Pharmaceuticals, Inc. ( Napo ), develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ( GI ) disease states. Jaguar family companies Napo and Napo Therapeutics, S.p.A., an Italian corporation Jaguar was established in Milan, Italy in 2021, are focused on expanding global crofelemer access and are developing new therapies for orphan and rare GI conditions. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp., is focused on developing novel prescription medicines derived from plants for mental health indications. Jaguar was founded in San Francisco, California, as a Delaware corporation on June 6, 2013 ( inception ). The Company was a majority-owned subsidiary of Napo until the close of the Company's initial public offering on May 18, 2015. The Company was formed to develop and commercialize first-in-class prescription and non-prescription products for companion animals. On July 31, 2017, Jaguar completed a merger with Napo pursuant to the Agreement and Plan of Merger dated March 31, 2017, by and among Jaguar, Napo, Napo Acquisition Corporation ( Merger Sub ), and Napo's representative (the Merger Agreement ). In accordance with the terms of the Merger Agreement, upon the completion of the merger, Merger Sub merged with and into Napo, with Napo surviving as the 1 Table of Contents wholly owned subsidiary (the Merger or Napo Merger ).